The substance requires specific conditions to preserve molecular structure
And the pipeline with over 290 registered clinical trials and early data pointing toward addiction, neurodegeneration, and beyond suggests the story is nowhere near its final chapter
it fundamentally changes the compounds three-dimensional conformation, its receptor binding geometry, and its metabolic stability compared to linear analogues
It's important to note that semaglutide carries a boxed warning about the risk of thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
Divi's Laboratories is already supplying semaglutide components globally Price compression will occur Not immediately, and not to generic-drug levels, but a ~50% reduction from current branded pricing is a reasonable baseline expectation based on biosimilar precedent in other biologic classes New formulations will compete Novo Nordisk's oral semaglutide (approved December 2025 by the FDA and launched in early 2026) and the newly FDA-approved once-daily oral GLP-1 orforglipron (Foundayo, approved April 1, 2026) represent the manufacturer's strategy for maintaining market share through innovation beyond the injectable The arrival of biosimilar competition does not mean branded products disappear
M.BoadaM.et al
